ArticleFrontiers in oncology2026
Tumor cells-derived CXCL17 is associated with up-regulated neutrophil to monocyte ratio and predicts poor prognosis in oral squamous cell carcinoma.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
CXCL17, the most recently identified member of the chemokine family, has been implicated in angiogenesis, tumorigenesis, infection, and inflammation across various tumors. However, the expression profile and functional characterization of CXCL17 in oral squamous cell carcinoma (OSCC) remain inadequately explored. Based on our previous proteomics studies of OSCC patients, we reported the elevated CXCL17 expression in tumor tissues compared to adjacent non-tumor tissues. We originally characterized the prognostic value of CXCL17 and its spatial and temporal distribution in 72 OSCC tissue specimens by immunohistochemistry staining. Elevated CXCL17 expression was correlated with advanced tumor stage, increased distant metastasis, and significantly shorter overall survival. Multivariate analysis confirmed tumor cell-derived CXCL17 as an independent prognostic factor for overall survival. Additionally, we investigated the relationship between CXCL17 and peripheral blood indicators hypothesizing that CXCL17 may influence peripheral immune cell regulation. We revealed that higher CXCL17 in tumor center was associated with reduced postoperative neutrophil, preoperative monocyte and postoperative leukocyte. Moreover, CXCL17 levels in tumor center was correlated significantly with preoperative neutrophil-to-lymphocyte ratio (NLR) and postoperative lymphocyte-to-monocyte ratio (LMR). Elevated postoperative neutrophil-to-monocyte ratio (NMR) was associated with advanced TNM stage and higher lymph node metastasis rates, and was also observed in patients with postoperative distant metastasis. In summary, these findings suggest that CXCL17 contributes to OSCC progression and poor prognosis by modulating systemic immune responses and reshaping the tumor immune microenvironment, highlighting its potential as both a prognostic biomarker and a therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.